# Maple Syrup Urine Disease

#### Not Something to Put on Your Pancakes!!!

# What is Maple Syrup Urine Disease?

- It is also known as MSUD
- Metabolic disorder
- Autosomal recessive
- Incidence rate is 1:200,000 in live births
- The rate increases to 1:176 in inbred pop. like the Menonites

## **Effects of MSUD**

- Urine that smells like maple syrup
- Increased levels of branched-chain  $\alpha$ -ketoacids
- Progressive neurologic damage leading to high-pitched cry
- Irritability
- Spastic quadriparesis
- Seizures

## Effects cont....

- Central nervous system depression
- Coma
- Severe metabolic acidosis and Hypoglycemia
- Developmental disabilities: severe mental retardation
- Mortality: usually fatal within one month

## **Cause of MSUD**

#### Decreased function of the BCKD complex

# **More on the BCKD Complex**

- Multienzyme complex w/ 3 catalytic subunits
- Specific kinase inactivates
- Specific phosphatase activates
- Oxidatively decarboxylates ketoacid substrate
- •Located on matrix side of mito. inner membr.
- Genes located on sep. autosomes (autosomal recessive transmission)
- Similar to Pyruvate & α Ketoglut. Dehydrogenase complexes









# Why does this decreased function occur?

Gene rearrangement & Point mutations

• Affect gene txn, transcript processing, and transcript stability by abberant splicing or early termination

• Pt. Mutations can lead to unstable prtns or a prtn that can not be imported into the mito.

Table 3	Mutations affecting the human branched-chain <i>a</i> -ketoacid dehydrogenase complex					
		Nucleotide change	Exon	Intron	Functional change	Reference
E1¤ GM649		$T_{1339} \rightarrow A$	9.	_	Y393N	Zhang et al(1989) Fisher et al (1991) Matsuda et al (1990)
Е1 <i>в</i> LK		11 bp del	1	_	Early stop codon	(Nobukuni et al (1991b)
E2 GM136	6	$G_{684} \rightarrow T$	6	-	E163*	Fisher et al (1989) Fisher et al (1993)
GM612	Al	2 bp del	2	<u>←</u>	Stop	Chuang et al (1991)
Q. <u></u>	A2	$G_{684} \rightarrow T$	6	_	E163*	Fisher et al (1993)
WG34	AI	17 bp insert	_	4	Splice error	Fisher et al (1989)
	A2	$T_{041} \rightarrow G$	7	_	F215C	Fisher et al (1991)
	1,12	- 0.4 1				Chuang et al (1991)
Ech	A 1	2 bp del	2	_	Stop	Fisher et al (1989)
Lon	Δ2	2 bn del	_	5	Splice error	Chuang et al (1991)
	712	P		-	••••••••••••••••••••••••••••••••••••••	Fisher et al (1993)
AT	Δ 1	3 bn del	4	_	E27 lost	Fisher et al (1989)
AL/	30		5	_	177T	Chuang et al (1991)
TUI	<b>n</b> 4	G del	-	8	Splice error	Mitsubuchi et al (1991a)
1 13 1		0 80		0	Exon 8 del	Nobukuni et al (1991a)
I T	A Í	20 kh genomic del	6_11	6-10	Truncated	Herring et al (1992)
LF	A1 A2		8	-	Splice error	
	AZ	$O_{1031} \rightarrow A$			Exon 8:8-10 del	
		2	3		Solice error	Herring et al (1991)
BH	AI	· · · · · · · · · · · · · · · · · · ·	Z	—	Exon 7 del	Horning of an (1994)
		<sup>o</sup>				
	A2	· · · · · ·			INO ITAIISCIIPI	Fisher at al (1993)
TH2		$G_{684} \rightarrow T$	0	-	E103	Fisher et al (1295)
FHA		$G_{684} \rightarrow T$	6	<del></del>	E103*	$\mathbf{F} = \mathbf{F} = $
MF		2 bp del	2	·	Stop	FISHER CL al (1773)
			-		14 127	
			4 3 1	5.1	8 7	
			11 10	100 10		(2000)
	2					199
	5		3 4	5 5	7 6 7	40
	53					222
			9 9 5 6			



• Mitsubuchi and colleagues did PCR analysis of the E2 subunit cDNA on the patient's family

# **Types of MSUD**

Three types related to branched-chain α-ketoacid dehydrogenase complex (BCKD)

•Type IA: defect in the E1-alpha subunit

- •Type IB: defect in the E1-beta subunit
- Type II: defect in the E2 subunit

Note that E3 is not mentioned b/c it's involved in 3 major pthwys and infants die w/severe lactic acidosis

### Forms of MSUD

MSUD is also classified by age of onset, decarboxylase activity, and blood levels of BCKA

Three clinical phenotypes

• <u>Mild intermediate form</u>: decarboxylase activity 5-25% of normal; blood levels of Leu, Ile, and Val 5-10 fold normal; developmentally normal to moderately retarded

• <u>Intermittent form</u>: occurs later in childhood as a result of infection or stress; crisis resembles classic MSUD and can be fatal

• <u>Thiamine-responsive form</u>: decarboxylase activity 20% of norma; blood leucine levels of BCKA 3 fold normal

#### Treatment

- Restricted diet in branched-chain amino acids and prtn
- Daily Pharmacological doses of B1 increase tolerance for prtn while keeping norm leucine levels
- High doses of Thiamine increase tolerance for BCAA

## **Future Goals**

• To understand how gene products interact w/each other in given genetic environment

• Identify which tissues require func. of BCKD

• Use gene therapy to get the wild type gene, gene replacement, or correct the mutation w/in tissue to the improve quality of life

#### References

1. Chuang, J. L.; Cox, R. P.; Chuang, D. T.: E2 transacylase-deficient (Type II) maple syrup urine disease: aberrant splicing of E2 mRNA caused by internal intronic deletions and associations with thiamine-responsive phenotype, J. Clin. Invest. 100:736-744, 1997

2. Herring, W. J.; Litwer, S.; Weber, J. L.; Danner, D. J.: Molecular genetic basis of maple syrup urine disease in a family with two defective alleles for branched chain acyltransferase and localization of the gene to human chromosome 1. *Am. J. Hum. Genet.* 48: 342-350, 1991.

**3.** Lau, K. S.; Herring, W. J.; Chuang, J. L.; Mckean, M.; Danner, D. J.; Cox, R. P.; Chuang, D. T.: **Structure of the gene** encoding dihydrolipoyl transacylase (E2) component of human branched chain alpha-keto acid dehydrogenase and characterization of an E2 pseudogene. *J. Biol. Chem.* 267: 24090-24096,1992.

4. Mitsubuchi, H.; Nobukuni, Y.; Akaboshi, I.; Indo, Y.; Endo, F.; Matsuda, I.: Maple syrup urine disease caused by a partial deletion in the inner E2 core domain of the branched chain alpha-keto acid dehydrogenase complex due to aberrant splicing: a single base deletion at a 5-prime-splice donor site of an intron of the E2 gene disrupts the consensus sequence in this region. J. Clin. Invest. 87: 1207-1211, 1991.

5. Montgomery; Conway; Spector; Chappell: Biochemistry: a case oriented approach. Ed. Underdown. St. Louis: Mosby-Year Book, Inc. 6th ed., 1996.

6. Peinemann, F.; Danner, D. J.: Maple syrup urine disease 1954 to 1993. J. Inher. Metab. Dis. 17: 3-15, 1994.

7. Turchany, J. M.; Leung, P. S. C.; Iwayama, L. T.; Jefferson, D. M; Ishida, J.; Yamaguchi, M.; Munoz, S.; Danner, D. J.; Dickson, E. R.; Gershwin, M. E.: Comparative metabolism and structure of BCKD-E2 in primary biliary cirrhosis. J. Autoim. 6 (4): 459-466, 1993.

8.http://www.ncbi.nlm.nih.gov:80/entrez/que...ed&tmpl=dispomimTemplate&list\_uids=248610

9. http://www.ncbi.nlm.nih.gov/cgi-bin/Entre...A3976.00],gene[1p31.3%A1p31.3]&Zoom

10. http://medlineplus.adam.com/ency/article/000373.htm

11. http://www.vtmednet.org/~m145037/vhgi mem/nbsman/msud.htm

